Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients with Advanced Solid Tumours
- First Posted Date
- 2021-11-10
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Kazia Therapeutics Limited
- Target Recruit Count
- 32
- Registration Number
- NCT05114668
- Locations
- 🇫🇷
Centre Léon Bérard, Lyon, France
🇫🇷Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France
Mass Balance Recovery, Metabolite Profile, and Metabolite Identification of [14C]-Paxalisib in Healthy Male Subjects
- Conditions
- Healthy
- Interventions
- Drug: [14C]-Paxalisib Capsule
- First Posted Date
- 2021-08-19
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Kazia Therapeutics Limited
- Target Recruit Count
- 6
- Registration Number
- NCT05012670
- Locations
- 🇬🇧
Quotient Sciences, Nottingham, United Kingdom
Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma
- First Posted Date
- 2018-05-11
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Kazia Therapeutics Limited
- Target Recruit Count
- 30
- Registration Number
- NCT03522298
- Locations
- 🇺🇸
University of California Los Angeles - Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.
- Conditions
- Peritoneal NeoplasmsOvarian NeoplasmsFallopian Tube Neoplasms
- First Posted Date
- 2016-09-16
- Last Posted Date
- 2020-04-20
- Lead Sponsor
- Kazia Therapeutics Limited
- Target Recruit Count
- 28
- Registration Number
- NCT02903771
- Locations
- 🇺🇸
Peggy and Charles Stephenson Cancer Center, OU Health Sciences Center, Oklahoma City, Oklahoma, United States
🇺🇸Lifespan Cancer Institute, Rhode Island Hospital, Providence, Rhode Island, United States
🇺🇸Mary Crowley Cancer Research Center, Dallas, Texas, United States
Phenoxodiol in Treating Patients With Refractory Solid Tumors
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-03-26
- Lead Sponsor
- Kazia Therapeutics Limited
- Target Recruit Count
- 36
- Registration Number
- NCT00022295
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States